Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
Department of Internal Medicine I, University Hospital Bonn, 53127 Bonn, Germany.
Int J Mol Sci. 2019 Sep 3;20(17):4307. doi: 10.3390/ijms20174307.
Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-induced killer cells (CIKs) are considered to be major cytotoxic immunologic effector cells. Usually cancer cells are able to suppress antitumor responses by secreting immunosuppressive factors. CIKs have significant antitumor activity and are capable of eradicating tumors with few side effects. They are a very encouraging cell population used against hematological and solid tumors, with an inexpensive expansion protocol which could yield to superior clinical outcome in clinical trials employing adoptive cellular therapy combination. In the last decade, clinical protocols have been modified by enriching lymphocytes with CIK cells. They are a subpopulation of lymphocytes characterized by the expression of CD3+ and CD56+ wich are surface markers common to T lymphocytes and natural killer NK cells. CIK cells are mainly used in two diseases: in hematological patients who suffer relapse after allogeneic transplantation and in patients with hepatic carcinoma after surgical ablation to eliminate residual tumor cells. Dendritic cells DCs could play a pivotal role in enhancing the antitumor efficacy of CIKs.
过继细胞免疫疗法（ACI）是治疗多种癌症的一种很有前途的方法。细胞因子诱导的杀伤细胞（CIKs）被认为是主要的细胞毒性免疫效应细胞。通常，癌细胞能够通过分泌免疫抑制因子来抑制抗肿瘤反应。CIKs 具有显著的抗肿瘤活性，能够消除肿瘤，副作用很少。它们是一种非常有前途的细胞群体，可用于治疗血液系统和实体肿瘤，其扩增方案成本低廉，在采用过继细胞疗法联合治疗的临床试验中可能会产生更好的临床结果。在过去的十年中，临床方案已经通过用 CIK 细胞丰富淋巴细胞进行了修改。它们是淋巴细胞的一个亚群，其特征是表达 CD3+和 CD56+，这是 T 淋巴细胞和自然杀伤 NK 细胞的共同表面标记物。CIKs 主要用于两种疾病：同种异体移植后复发的血液系统患者，以及手术消融后消除残余肿瘤细胞的肝癌患者。树突状细胞（DCs）在增强 CIK 的抗肿瘤疗效方面可能发挥关键作用。
